SAFETY AND EFFICACY OF INTRAMUSCULAR ELECTROTRANSFER OF PLASMID AMEP IN PATIENTS SUFFERING FROM ADVANCED OR METASTATIC MELANOMA: AN OPEN-LABEL PHASE I/II CLINICAL TRIAL THE AIMM STUDY (AMEP IN METASTATIC MELANOMA)

Trial Profile

SAFETY AND EFFICACY OF INTRAMUSCULAR ELECTROTRANSFER OF PLASMID AMEP IN PATIENTS SUFFERING FROM ADVANCED OR METASTATIC MELANOMA: AN OPEN-LABEL PHASE I/II CLINICAL TRIAL THE AIMM STUDY (AMEP IN METASTATIC MELANOMA)

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs BA 015 (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms AIMM
  • Most Recent Events

    • 10 Sep 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 13 Jun 2013 Planned End Date added 1 Mar 2014 according to ClinicalTrials.gov.
    • 24 Jan 2013 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top